BioAge Labs is expanding its lead drug candidate into diabetic macular oedema, with plans to start a phase 1b/2a trial in mid-2026. The clinical-stage biotechnology company...
The USC Clinical Trial Recruitment Lab will fund four projects testing how AI can strengthen recruitment for Alzheimer’s trials. The initiative, dedicated to accelerating and improving...
Insilico Medicine has agreed a US$66m deal with a Chinese biotech for half of the rights to a brain-penetrant Parkinson’s drug. Under the agreement, the artificial...
Scientists have developed a nanoparticle strategy to broaden which disease-causing proteins medicines can target, giving options for dementia and brain cancer. A perspective outlines an approach...
Exciva has raised US$59.4m in series B funding to support a phase 2 trial of its Alzheimer’s therapy. The clinical-stage biopharmaceutical company is developing treatments for...
SciNeuro Pharmaceuticals has entered a worldwide licensing and collaboration agreement with Novartis to advance its amyloid beta-targeted antibody programme for Alzheimer’s disease. The programme has identified...
